LifeCycle Pharma A/S to Host Conference Call Announcing Interim Report for 3rd Quarter 2009

Investor Service Announcement no. 6/2009			

To: NASDAQ OMX Copenhagen          	Hørsholm, Denmark, November 6, 2009



LifeCycle Pharma A/S to Host Conference Call Announcing 
Interim Report for 3rd Quarter 2009 - results from January 1 to September 30,
2009 

LifeCycle Pharma A/S (OMX: LCP) will announce the Interim Report for 3rd
Quarter 2009 on Wednesday November 11, 2009. LCP's Management will host an
accompanying conference call to discuss the financial results on Thursday
November 12, 2009 at 14:30 CET (Denmark); 13:30 GMT (London), 08:30 AM ET (New
York), 05:30 AM PT 
(San Francisco).  

To access the live conference call, please dial one of the following numbers:
+1 866 966 5335 (US)
+44 (0) 2030 032 666 (UK)
+45 (0) 32 729 273 (DK)

If you cannot access the conference call by mobile phone this could be caused
by some mobile providers blocking the mobile phone from getting access to
certain numbers i.e. toll-free numbers. Therefore please use the DK number (+45
(0) 32 729 273) or the UK number (+44 (0) 2030 032 666) as these numbers are
not toll-free numbers. 

An audio replay of the conference call will be available on www.lcpharma.com
from Thursday, November 12, 2009 at 17:30 CET (Denmark); 16:30 GMT (London),
11:30 AM ET (New York), 08:30 AM PT (San Francisco), through Friday, December
11, 2009 by dialing +44 (0) 2081 961 998 (UK) or +1 866 583 1035 (US), and
entering access code 
8403264#.

For more information, please contact:

Peter Schøtt Knudsen
Head of Investor Relations
Phone: + 45 2055 3817	
Email: PSK@lcpharma.com	

	
About LifeCycle Pharma A/S (LCP)
Based in Hørsholm, Denmark, with an office in New York, LCP is an emerging
specialty pharmaceutical company. Clinical development is the core of LCP's
effort to develop a product portfolio which includes products for
immunosuppression, specifically organ transplantation, and products to combat
certain cardiovascular diseases. As a fully integrated company, LCP adapts new
technologies on a fast commercial timetable. LCP's unique, patented delivery
technology, MeltDose®, can improve absorption and bioavailability - at
low-scale up costs - not only for a broad spectrum of drugs already on the
market but also for new chemical entities. LCP has a cholesterol-lowering
product, Fenoglide®, currently on the U.S. market and a diversified near- and
medium-term pipeline with four product candidates in clinical trials and a
number of projects in preclinical development. LCP is listed on the NASDAQ OMX
Copenhagen under the trading symbol (OMX: LCP). 

For further information, please visit www.lcpharma.com.